Himalayas-1 randomizes 1:1 to rinzimetostat 400 mg daily plus darolutamide vs physician’s choice ARPI or docetaxel in mCRPC progressing after abiraterone. Radiographic PFS is the primary end point, ...
Sanoj Punnen, MD, highlights the importance of assessing and managing cardiovascular risk when initiating androgen deprivation therapy for patients with prostate cancer.
CONVERGE-01 enrolled progressive PSMA-positive mCRPC after 1-6 prior Lu-177–PSMA cycles, with universal ARPI exposure and 80% prior taxane use in the ASCO cohort. Fractionated CONV01-α on days 1 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results